1
The story
Our client approached us to help it evaluate the potential of a small molecule therapeutic vs. an antibody therapeutic for the prevention of cytomegalovirus (CMV) infection in a number of special populations in 7 major markets.
2
The solution
We designed a study to:
- Map clinical pathways for prevention, diagnosis, and treatment
- Identify current trends and future unmet needs in key market segments/patient populations
- Develop an ideal therapeutic product profile including efficacy, safety, formulation, cost, and compliance
- Forecast the current and future market size, and the impact of market events
- 40 KOL interviews in the US, Japan, and EU
- Extensive quantitative and qualitative secondary research
3
The outcome
GlobalData delivered clear insights into unmet needs, product uptake scenarios based on clinical attributes, and a comprehensive patient model/forecast, complete with specialty segments and impacts of potential market events.
An evaluation of the potential of a specific therapy for a top 10 pharma company
Let’s start building your custom solution
Enquire now
